Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$72,000.00

Specific and cell-permeable molecular probes of calpain function

FY 2011-12

Summary
The Calpain family of Ca2+-dependent proteases is involved in many physiological functions. Calpain dysfunction is implicated in many diseases. The greatest impact of Calpain proteases lies in their involvement in stroke, the third leading cause of death in Canada (source: Heart and Stroke Foundation). In addition to the damage done during hypoxic conditions of an ischemic stroke, the ischemic cascade contributes to a number of downstream effects even after the restoration of blood flow. The fact that over 88% of stroke survivors end up with some form of impairment or disability stresses the importance of battling this affliction and the need for new therapies. The low energy state of cells under anaerobic conditions shuts down the ATP-dependent ion exchange pumps, creating a large influx of Ca2+, thereby over-activating calpain. One of the targets of calpain is the Na+/Ca2+ exchanger which is cleaved during ischemia. The positive feedback loop rapidly pushes the cell down the death pathways of necrosis or apoptosis. Calpain inhibitors such as AK295 and SNJ1945 have been shown to reduce tissue damage upon experimental brain injury and stroke but have not been pursued further due to modest specificity. The grand challenge is to identify specific and potent calpain inhibitors that will not affect other cysteine proteases. Using the cyclic peptide methods developed recently in the Yudin lab, we will address the challenge of finding specific inhibitors for Calpains 1&2. Driven by a ground-breaking study published by Peter Davies (Nature 2008), we recently synthesized cyclic peptides for the unprimed area of the active site of the protease. This chemistry is based on a breakthrough disclosed by the Yudin lab in 2010 (JACS 2010, Chemical and Engineering News 2010, Faculty of 1000). Our cyclization technique allows facile incorporation of end-of-synthesis modifications to a key part in the structure, which we will use in order to fuse cyclic peptide inhibitors targeting both the primed and unprimed site of the calpain active site.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
399344-2011
Name nom
Yudin, Andrei
Department département
Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
72000
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
3
Application title
Specific and cell-permeable molecular probes of calpain function
Keyword
NSERC
Application summary
The Calpain family of Ca2+-dependent proteases is involved in many physiological functions. Calpain dysfunction is implicated in many diseases. The greatest impact of Calpain proteases lies in their involvement in stroke, the third leading cause of death in Canada (source: Heart and Stroke Foundation). In addition to the damage done during hypoxic conditions of an ischemic stroke, the ischemic cascade contributes to a number of downstream effects even after the restoration of blood flow. The fact that over 88% of stroke survivors end up with some form of impairment or disability stresses the importance of battling this affliction and the need for new therapies. The low energy state of cells under anaerobic conditions shuts down the ATP-dependent ion exchange pumps, creating a large influx of Ca2+, thereby over-activating calpain. One of the targets of calpain is the Na+/Ca2+ exchanger which is cleaved during ischemia. The positive feedback loop rapidly pushes the cell down the death pathways of necrosis or apoptosis. Calpain inhibitors such as AK295 and SNJ1945 have been shown to reduce tissue damage upon experimental brain injury and stroke but have not been pursued further due to modest specificity. The grand challenge is to identify specific and potent calpain inhibitors that will not affect other cysteine proteases. Using the cyclic peptide methods developed recently in the Yudin lab, we will address the challenge of finding specific inhibitors for Calpains 1&2. Driven by a ground-breaking study published by Peter Davies (Nature 2008), we recently synthesized cyclic peptides for the unprimed area of the active site of the protease. This chemistry is based on a breakthrough disclosed by the Yudin lab in 2010 (JACS 2010, Chemical and Engineering News 2010, Faculty of 1000). Our cyclization technique allows facile incorporation of end-of-synthesis modifications to a key part in the structure, which we will use in order to fuse cyclic peptide inhibitors targeting both the primed and unprimed site of the calpain active site.